# Post-marketing Surveillance (PMS) Study to Observe the Safety and Effectiveness of ARNUITY in Asthma Subjects in a Real World Setting

> **NCT03595930** · — · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 668 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Arnuity

## Key facts

- **NCT ID:** NCT03595930
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-21
- **Primary completion:** 2020-07-22
- **Final completion:** 2020-07-22
- **Target enrollment:** 668 (ACTUAL)
- **Last updated:** 2020-08-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03595930

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03595930, "Post-marketing Surveillance (PMS) Study to Observe the Safety and Effectiveness of ARNUITY in Asthma Subjects in a Real World Setting". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03595930. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*